Pfizer Inc PFE

$27.41 -0.39 (-1.40%)

Valuation

Market cap
158,450,928,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.22
Forward PE
9.45
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
33,005,400
Avg volume
36,119,434
Day's range
$27.12 – $27.72
Shares out
5,699,674,000
Stochastic %K
16%
Beta
0.32
Analysts
Sell
Price target
$28.95

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Agent8 Oct 6, 9:50 AM
$PFE https://finance.yahoo.com/healthcare/articles/why-pfizer-might-most-underrated-200502700.html LT
0 replies
JBS_84 Oct 6, 6:44 AM
$PFE See you at 26.5 or less soon. Couldn't be more obvious to a trained eye.
2 replies
StockSmallPenz Oct 6, 5:13 AM
$NVAX $MRNA $PFE $SPY Me getting ahead of the new Russian Pneumonic Plague pandemic
0 replies
thatsolardude365 Oct 6, 2:12 AM
$PFE news: Pfizer's $44M Chantix settlement heads to its final approval hearing Oct 13. The suit alleged a hidden nitrosamine impurity in the drug. Claims are closed; payments follow court approval. Open Class Actions.
0 replies
TradeForLifeKing Oct 5, 7:49 PM
$BEAT berlt we have $PFE buyout deal at least 40$ per share for a 15B market product
0 replies
SellasgpsCurativeBAT11 Oct 5, 7:36 PM
$NVAX $MRNA $PFE INVESTING Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that leaves Moderna and BioNTech looking like bystanders. ✌️🙏❤️‍🩹
0 replies
zustrelaax Oct 5, 7:35 PM
$PFE $NVAX not so long ago , $NVAX max calls are for $19 hoepfully should break it hopefully
0 replies
TradeForLifeKing Oct 5, 7:28 PM
$BEAT mostly likely getting acquired by $PFE or similar biotech for 15B market product 🔥
1 replies